ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

This study has been terminated.
(Slow recruitment)
Information provided by:
Hoffmann-La Roche Identifier:
First received: April 16, 2007
Last updated: March 19, 2008
Last verified: March 2008
This 2 arm study will assess the immunological benefits of adding Fuzeon to an antiretroviral regimen in HIV-infected, Fuzeon-naive patients with a CD4 cell count <250 cells/mm3 and an HIV RNA viral load <400 copies/mL. Eligible patients will be randomized to receive Fuzeon 90mg bid sc in addition to their current antiretroviral therapy, or to continue their current antiretroviral therapy alone. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.

Condition Intervention Phase
HIV Infections
Drug: enfuvirtide [Fuzeon]
Drug: Antiretroviral therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open Label Study to Determine the Immunological Benefits of Adding Fuzeon to an Antiretroviral Regimen in HIV-Infected Fuzeon-naïve Patients With Sustained HIV Viral Suppression

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Mean change in CD4 cell count from baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in HIV RNA from baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Change in HIV RNA and CD4 cell count [ Time Frame: Weeks 24-48 ] [ Designated as safety issue: No ]
  • Correlation between CD4 count and HIV RNA; OIs; QoL; ADEs; SAEs. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Estimated Study Completion Date: May 2009
Arms Assigned Interventions
Experimental: 1 Drug: enfuvirtide [Fuzeon]
90mg sc bid
Drug: Antiretroviral therapy
As prescribed
Active Comparator: 2 Drug: Antiretroviral therapy
As prescribed


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • documented chronic HIV infection;
  • currently receiving a stable antiretroviral regimen;
  • CD4 cell count <250 cells/mm3;
  • HIV RNA viral load <400 copies/mL for >12 months.

Exclusion Criteria:

  • prior exposure to Fuzeon;
  • prior non-adherence to antiretroviral treatment regimens;
  • active opportunistic infection;
  • currently taking, or anticipated to take during the study, any immunomodulator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00461266

Carlton, Australia
Darlinghurst, Australia
Melbourne, Australia
Miami, Australia
Perth, Australia
South Yarra, Australia
Sydney, Australia
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Clinical Trials, Study Director, Hoffmann-La Roche Identifier: NCT00461266     History of Changes
Other Study ID Numbers: ML19355 
Study First Received: April 16, 2007
Last Updated: March 19, 2008
Health Authority: Australia: South Eastern Sydney Area Health Service

Keywords provided by Hoffmann-La Roche:
Treatment Experienced

Additional relevant MeSH terms:
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
HIV Fusion Inhibitors
Molecular Mechanisms of Pharmacological Action
Viral Fusion Protein Inhibitors processed this record on May 22, 2016